Compare NUVB & UAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | UAN |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 2020 | 2008 |
| Metric | NUVB | UAN |
|---|---|---|
| Price | $4.30 | $110.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | ★ 5.1M | 18.7K |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 9.41% |
| EPS Growth | ★ 71.56 | 61.98 |
| EPS | N/A | ★ 11.04 |
| Revenue | $62,902,000.00 | ★ $606,038,000.00 |
| Revenue This Year | $209.36 | N/A |
| Revenue Next Year | $41.60 | N/A |
| P/E Ratio | ★ N/A | $10.15 |
| Revenue Growth | ★ 698.96 | 15.36 |
| 52 Week Low | $4.05 | $93.43 |
| 52 Week High | $9.75 | $139.50 |
| Indicator | NUVB | UAN |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 25.99 |
| Support Level | $4.17 | $107.10 |
| Resistance Level | $5.11 | $112.40 |
| Average True Range (ATR) | 0.24 | 3.51 |
| MACD | 0.07 | -1.10 |
| Stochastic Oscillator | 70.55 | 0.00 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.